Promising combo for tough leukemia falls short in early trial
NCT ID NCT05268003
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 21 times
Summary
This study tested whether adding the drug ponatinib to a standard chemotherapy mix plus venetoclax could help people whose T-cell acute lymphoblastic leukemia (T-ALL) had come back or stopped responding to treatment. Only 4 people took part before the study was stopped early. The goal was to see how many patients achieved complete remission or near-complete remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.